RxDoctor Payments Data

Kristen Mrozek

Primary Care · Saint Cloud, MNNPI 1851049027

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 19 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 21.1% — the pattern of someone who eats at a lot of different presentations.

$341in general payments, 2019–2025

Across 19 payments — averaging $17.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$72
  • GSK$49
  • Organon$38
  • Novartis$34
  • AbbVie$33
  • Exact Sciences$24
  • plus $91 from 6 others

What the payments were for

  • Food & beverage$341100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$341 in reported general payments places this provider in the 70th percentile of 54 primary care providers in Minnesota.

See all primary care providers in Minnesota

Medicare billing

Part B allowed, 2024
$24,896
Medicare patients
106
Services billed
548

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin14$10,513
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,160
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$5,114
Potassium Chloride16$4,109
Advair HfaFluticasone Propion/Salmeterol12$3,666
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$1,446
Bupropion XlBupropion Hcl36$1,175
Atorvastatin Calcium44$799
Rosuvastatin Calcium50$743
Levothyroxine Sodium47$740
Amlodipine Besylate56$731
Escitalopram Oxalate43$662
Albuterol Sulfate HfaAlbuterol Sulfate21$626
Omeprazole28$609
Metoprolol Succinate34$606

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKAnoro Ellipta$49$5,16012 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 54 primary care providers in Minnesota.

Other primary care in Saint Cloud

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →